Back

Persistence to long-term PCSK9 inhibitors treatment and its effectiveness in familial hypercholesterolemia: data from the SAFEHEART study

27 August 2022 (12:15 - 13:00)
Organised by:
Congress Presentation Part of: Lipids - Drug therapy 2 Drug therapy ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Doctor Rodrigo Alonso

Centre for Advanced Metabolic Medicine and Nutrition, Santiago (Chile)

6 More presentations in this session

Presentation thumbnail
Effect on cholesterol remnants and residual lipid risk with PCSK9 inhibitors: the LIPID-REAL Registry
Doctor A. Cordero (Alicante, ES)
Abstract Slides
Presentation thumbnail
Simulation study on LDL cholesterol target attainment, ASCVD events, and treatment cost of bempedoic acid in a representative German cohort of high- and very-high-CV risk patients
Doctor J. Katzmann (Leipzig, DE)
Abstract Slides
Presentation thumbnail
Effect of SLCO1B1 genotypes on statin intolerance and response to statins
Mrs L. Davis (Harefield, GB) Doctor T. Khan (Harefield, GB)
Abstract Slides
Presentation thumbnail
LDL-C goal achievement and lipid-lowering therapy in patients by atherosclerotic cardiovascular disease subtype: the SANTORINI study
Professor K. Ray (London, GB)
Abstract Slides
Presentation thumbnail
Trends in management of cardiovascular risk factors in young adults who go on to develop coronary artery disease
Doctor D. Vikulova (Vancouver, CA)
Abstract Slides

Access the full session

Session thumbnail
Lipids - Drug therapy 2

The Event

Event poster

ESC Congress 2022

27 August 2022 12:15 CET
You may be interested in
thumbnail
Webinar
Unmet needs in lipid management: treatment goals and how to achieve them
thumbnail
Webinar
Risk assessment and lipid management in primary prevention
thumbnail
Webinar
New trial evidence in the field of lipid management

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources